Bayer
-
Bayer Pushes Ahead With Parkinson’s Cell Therapy on Heels of Positive Phase 1 Data
A Bayer cell therapy for Parkinson’s disease has met primary and secondary goals of its first test in humans, and the pharmaceutical giant is now planning for a larger Phase 2 clinical trial expected to begin enrollment in the first half of next year.
-
Aiming to treat Parkinson’s by replacing neurons, Aspen Neuroscience nabs $147M
Aspen Neurosciences is developing a cell therapy that uses a patient’s own stem cells to develop a personalized treatment for Parkinson’s disease. The approach is slightly different than that of Bayer, whose experimental Parkinson’s cell therapy is made from stem cells sourced from healthy donors.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Pharma, Artificial Intelligence, BioPharma
Bayer reloads Leaps with €1.3 billion to step up investments in biotech innovation
Bayer is committing another €1.3 billion to Leaps by Bayer, the company’s investment arm, to support additional investments in companies developing innovative technologies in healthcare and agriculture. In addition to backing companies developing cell and gene therapies, Leaps has also deployed its cash to startups developing artificial intelligence technologies for a range of applications.
-
Pfizer, Bayer each strike up deals to add in-vivo gene editing to pipeline mix
As the annual J.P. Morgan HealthCare Conference kicked off Monday, two pharma giants unveiled deals that give them access to in-vivo gene editing technologies. Pfizer is teaming up with Beam Therapeutics to develop new base-editing therapies while Bayer hopes to develop new medicines with the in-vivo CRISPR editing tools of Mammoth Biosciences.
-
Pharma, Health Services, Health Tech
Bayer, One Drop release digital health program for heart disease
The app lets people track their metrics through connected devices, and access health coaching and educational materials. It’s one of multiple that Bayer and One Drop plan to develop together in the future.
-
Bayer kidney disease drug gets FDA nod, pitting it against AstraZeneca, J&J meds
The FDA has approved Bayer’s Kerendia to treat chronic kidney disease in patients with type 2 diabetes. The drug is the first in its class, giving the pharma giant an alternative way to compete against medicines already marketed by AstraZeneca and Johnson & Johnson.
-
Bayer’s investment arm leads digital health startup’s $90M round
Leaps by Bayer led a $90 million investment round into Ada, a German digital health startup with an AI-based symptom checker. As part of the deal, the two companies are also striking a broader strategic partnership.
-
Bayer paying up to $4B for gene therapy pioneer AskBio
The deal, offering $2 billion up front and $2 billion in future milestone payments, includes a gene therapy manufacturing facility and a pipeline that includes treatments for Parkinson’s and congestive heart failure.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
Startups, Artificial Intelligence, BioPharma
Recursion raises $239M in Series D, partners with lead investor Bayer
The partnership includes a $30 million upfront payment from Bayer and potentially more than $100 million in milestones per program generated through the partnering of the German drugmaker’s molecule library and Recursion’s artificial intelligence-based drug discovery platform.
-
Triumvira Immunologics raises $55M in Series A funding round for new form of cancer cell therapy
The company hopes to use the money to bring its T-cell antigen coupler cell therapy technology – currently in preclinical development – into human clinical trials. German drugmaker Bayer’s venture capital arm led the round.
-
Bayer to acquire KaNDy Therapeutics in $875M women’s health play
KaNDy’s lead product candidate, NT-814, is a non-hormonal treatment for symptoms of menopause. The drug completed Phase IIb testing and is slated to start Phase III testing next year.
-
These drug patents are expected to expire in 2020
According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. Two reports list 18 drugs as losing patent protection or exclusivity, though not all drugs listed here will necessarily face generic or biosimilar competition in 2020.
-
Bayer’s tumor-agnostic cancer drug gets European nod
Bayer said Monday that the European Medicines Agency had approved Vitrakvi for NTRK fusion-positive cancers. The drug won U.S. Food and Drug Administration accelerated approval in November.
-
Report: Swiss drugmaker Roche among several large firms targeted by hackers
According to an analysis, evidence pointed to a Chinese hacking group. German drugmaker Bayer was also targeted in April, apparently by Chinese hackers who used the same malware.